1. Home
  2. AEXA vs LXRX Comparison

AEXA vs LXRX Comparison

Compare AEXA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AEXA
  • LXRX
  • Stock Information
  • Founded
  • AEXA 2025
  • LXRX 1995
  • Country
  • AEXA United States
  • LXRX United States
  • Employees
  • AEXA N/A
  • LXRX N/A
  • Industry
  • AEXA
  • LXRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AEXA
  • LXRX Health Care
  • Exchange
  • AEXA Nasdaq
  • LXRX Nasdaq
  • Market Cap
  • AEXA 552.5M
  • LXRX 541.5M
  • IPO Year
  • AEXA 2025
  • LXRX 2000
  • Fundamental
  • Price
  • AEXA $10.98
  • LXRX $1.48
  • Analyst Decision
  • AEXA
  • LXRX Buy
  • Analyst Count
  • AEXA 0
  • LXRX 5
  • Target Price
  • AEXA N/A
  • LXRX $3.23
  • AVG Volume (30 Days)
  • AEXA 360.3K
  • LXRX 2.2M
  • Earning Date
  • AEXA 01-01-0001
  • LXRX 11-06-2025
  • Dividend Yield
  • AEXA N/A
  • LXRX N/A
  • EPS Growth
  • AEXA N/A
  • LXRX N/A
  • EPS
  • AEXA N/A
  • LXRX N/A
  • Revenue
  • AEXA N/A
  • LXRX $70,864,000.00
  • Revenue This Year
  • AEXA N/A
  • LXRX $66.55
  • Revenue Next Year
  • AEXA N/A
  • LXRX N/A
  • P/E Ratio
  • AEXA N/A
  • LXRX N/A
  • Revenue Growth
  • AEXA N/A
  • LXRX 1255.21
  • 52 Week Low
  • AEXA $10.53
  • LXRX $0.28
  • 52 Week High
  • AEXA $11.91
  • LXRX $1.66
  • Technical
  • Relative Strength Index (RSI)
  • AEXA N/A
  • LXRX 54.09
  • Support Level
  • AEXA N/A
  • LXRX $1.36
  • Resistance Level
  • AEXA N/A
  • LXRX $1.64
  • Average True Range (ATR)
  • AEXA 0.00
  • LXRX 0.12
  • MACD
  • AEXA 0.00
  • LXRX 0.01
  • Stochastic Oscillator
  • AEXA 0.00
  • LXRX 64.13

About AEXA American Exceptionalism Acquisition Corp. A

American Exceptionalism Acquisition Corp A is a blank check company.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: